A Study on Pulmonary Tuberculosis and Risk Factors in New and Re-Treated Presumptive Patients at Wad Madani Tuberculosis Center, Sudan (2018-2019): A Cross-Sectional Study
Introduction: The increase
in cases of drug-resistant pulmonary tuberculosis, especially in endemic areas, is mainly associated with re-treatment,
although resistant tubercle bacilli can be easily transmitted between all
susceptible persons.Objective:The study aimed to describe
pulmonary tuberculosis, risk factors and MDR in new and re-treated suspected
patients attending Wad Madani Tuberculosis Center that provides service in
central Sudan.Methods: Cross-sectional laboratory
based study among 300 presumptive pulmonary tuberculosis patients during 2018
and 2019 was conducted.Cases were
divided into new and re-treated. Mycobacterium tuberculosis DNA and rpoB gene
of multi-drug resistance (MDR) were detected in sputum samples by GeneXpert
assay as manufacturer instructions. Results:
References
[1]
Sudan, Federal Ministry of Health, PHC, Communicable and Noncommunicable Diseases Directorate (2018) Sudan National TB Management Guidelines.
[2]
Getahun, B., Ameni, G., Biadgilign, S. and Medhin, G. (2011) Mortality and Associated Risk Factors in a Cohort of Tuberculosis Patients Treated under DOTS Programme in Addis Ababa, Ethiopia. BMC Infectious Diseases, 11, Article No. 127. https://doi.org/10.1186/1471-2334-11-127
[3]
Stop TB Partnership (2004) Compendium of Indicators for Monitoring and Evaluation National Tuberculosis Programs. World Health Organization, Geneva, WHO/HTM/TB/2004.344. http://apps.who.int/iris/bitstream/10665/68768/1/WHO_ HTM_TB_2004.344.pdf
[4]
Romieu and Trenga, C. (2001) From Exposure to Disease: The Role of Environmental Factors in Susceptibility to and Development of Tuberculosis. Epidemiologic Reviews, 23, 288-301. https://doi.org/10.1093/oxfordjournals.epirev.a000807
[5]
Abdallaha, T.M., et al. (2012) Provider-Initiated HIV Testing and Counseling among Tuberculosis Patients in Kassala, Eastern Sudan. Journal of Infection and Public Health, 5, 63-66. https://doi.org/10.1016/j.jiph.2011.10.001
[6]
Joshi, R., Nienhaus, A. and Diel, R. (2005) Review of Epidemiological Studies on the Occupational Risk of Tuberculosis in Low-Incidence Areas. Respiration, 72, 431-446. https://doi.org/10.1159/000086261
[7]
Boutayeb, A., Lamlili, E.N.M., Boutayeb, W., Maamri, A., Ziyyat, A. and Ramdani, N. (2012) The Rise of Diabetes Prevalence in the Arab Region. Open Journal of Epidemiology, 2, 55-60. https://doi.org/10.4236/ojepi.2012.22009
[8]
International Diabetes Federation (2013) Diabetes Atlas. 6th Edition, Brussels. http://www.idf.org/diabetesatlas
[9]
WHO (2018) Multidrug-Resistant Tuberculosis (MDR-TB). https://www.who.int/tb/areas-of-work/drug-resistant-tb/MDR-RR_TB_factsheet_2018_Apr2019.pdf?ua=1
[10]
Seaworth, B.J. and Griffith, D.E. (2017) Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Microbiology Spectrum, 5, 2. https://doi.org/10.1128/microbiolspec.TNMI7-0042-2017
[11]
Dean, A.S., Cox, H. and Zignol, M. (2017) Epidemiology of Drug-Resistant Tuberculosis. Advances in Experimental Medicine and Biology, 1019, 209-220. https://doi.org/10.1007/978-3-319-64371-7_11
[12]
Wilson, J.W. and Tsukayama, D.T. (2016) Extensively Drug-Resistant Tuberculosis: Principles of Resistance, Diagnosis, and Management. Mayo Clinic Proceedings, 91, 482-495. https://doi.org/10.1016/j.mayocp.2016.01.014
[13]
Ahuja, S.D., Ashkin, D., Avendano, M., et al. (2012) Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-Analysis of 9,153 Patients. PLOS Medicine, 9, e1001300.
[14]
Meressa, D., Hurtado, R.M., Andrews, J.R., et al. (2015) Achieving High Treatment Success for Multidrug-Resistant TB in Africa: Initiation and Scale-Up of MDRTB Care in Ethiopia—An Observational Cohort Study. Thorax, 70, 1181-1188. https://doi.org/10.1136/thoraxjnl-2015-207374
[15]
Getachew, T., Bayray, A. and Weldearegay, B. (2013) Survival and Predictors of Mortality among Patients under Multi-Drug Resistant Tuberculosis Treatment in Ethiopia: St. Peter’s Specialized Tuberculosis Hospital, Ethiopia. International Journal of Pharmaceutical Sciences and Research, 4, 776-787.
[16]
IAMAT (2017) Sudan for Specific Travellers: Tuberculosis. https://www.iamat.org/country/sudan/risk/tuberculosis
[17]
Elmadhoun, W.M., Noor, S.K., Bushara, S.O., et al. (2016) Epidemiology of Tuberculosis and Evaluation of Treatment Outcomes in the National Tuberculosis Control Programme, River Nile State, Sudan, 2011-2013. Eastern Mediterranean Health Journal, 22, 95-102. https://doi.org/10.26719/2016.22.2.95
[18]
Elfaham, Z., Ibrahim, E., Ahmed, E., Mohammed, A. and Nour, B. (2021) Pulmonary Tuberculosis among Suspected Sudanese Patients in Wad Madani Tuberculosis Center. Open Journal of Medical Microbiology, 11, 298-307. https://doi.org/10.4236/ojmm.2021.114019
[19]
Hakeem, A., Hussain, M.S. and Sarwar, M.I. (2013) Gene Xpert MTB/RIF—A Novel Diagnostic Tool for Tuberculosis in Pulmonary Samples. IOSR Journal of Dental and Medical Sciences, 8, 1-3. https://doi.org/10.9790/0853-0820103
[20]
Chung-Delgado, K., et al. (2015) Mortality among MDR-TB Cases: Comparison with Drug-Susceptible Tuberculosis and Associated Factors. PLoS ONE, 10, e0119332. https://doi.org/10.1371/journal.pone.0119332
[21]
Dheda, K., Chang, K.C., Guglielmetti, L., et al. (2017) Clinical Management of Adults and Children with Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Microbiology and Infection, 23, 131-140. https://doi.org/10.1016/j.cmi.2016.10.008
[22]
Prasad, R., et al. (2018) Multidrug-Resistant Tuberculosis/Rifampicin-Resistant Tuberculosis: Principles of Management. Lung India: Official Organ of Indian Chest Society, 35, 78-81. https://doi.org/10.4103/lungindia.lungindia_98_17
[23]
WHO (2021, October 14) Fact Sheets. Tuberculosis. https://www.who.int/en/news-room/fact-sheets/detail/tuberculosis
[24]
Aricha, S., Kingwara, L., Mwirigi, N., Chaba, L., et al. (2019). Comparison of GeneXpert and Line Probe Assay for Detection of Mycobacterium tuberculosis and Rifampicin-Mono Resistance at the National Tuberculosis Reference Laboratory, Kenya. BMC Infectious Diseases, 19, Article No. 852. https://doi.org/10.1186/s12879-019-4470-9
[25]
Federal Ministry of Health of Ethiopia (FMOH) (2011) Tuberculosis Prevention and Control Programme: Special Issue for World TB Day.
[26]
Cheng, V.C.C., Yew, W.W. and Yuen, K.Y. (2015) Diagnostics in MDR-Tuberculosis. European Journal of Clinical Microbiology & Infectious Diseases, 24, 711-720. https://doi.org/10.1007/s10096-005-0039-1
[27]
Banaga, A.S., Siddiq, N.K., Alsayed, R.T., Babiker, R. and Elmusharaf, K. (2016) Prevalence and Presentation of Tuberculosis among Hemodialysis Patients in Khartoum, Sudan. Saudi Journal of Kidney Diseases and Transplantation, 27, 992-996. https://doi.org/10.4103/1319-2442.190873
[28]
Borgdor, M.W., Nagelkerke, N.J.D., Dye, C. and Nunn, P. (2000) Gender and Tuberculosis: A Comparison of Prevalence Surveys with Notification Data to Explore Sex Differences in Case Detection. The International Journal of Tuberculosis and Lung Disease, 4, 123-132.
[29]
Watkins, R.E. and Plant, A.J. (2006) Does Smoking Explain Sex Differences in the Global Tuberculosis Epidemic? Epidemiology & Infection, 134, 333-339. https://doi.org/10.1017/S0950268805005042
[30]
Lim, S.S., Vos, T., Flaxman, A.D., Danaei, G., Shibuya, K., Adair-Rohani, H., Amann, M. anderson, H.R. andrews, K.G., Aryee, M., et al. (2012) A Comparative Risk Assessment of Burden of Disease and Injury Attributable to 67 Risk Factors and Risk Factor Clusters in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010. The Lancet, 380, 2224-2260.
[31]
Giefing-Kroll, C., Berger, P., Lepperdinger, G. and Grubeck-Loebenstein, B. (2015) How Sex and Age Affect Immune Responses, Susceptibility to Infections, and Response to Vaccination. Aging Cell, 14, 309-321. https://doi.org/10.1111/acel.12326
[32]
Guess, T.E., Rosen, J.A. and McClelland, E.E. (2018) An Overview of Sex Bias in C. Neoformans Infections. Journal of Fungi (Basel), 4, pii: E49. https://doi.org/10.3390/jof4020049
[33]
Kherad, O., Hermann, F.R., Zellweger, J.P., Rochat, T., Jansen, J.P., et al. (2009) Clinical Presentation, Demographics and Outcome of Tuberculosis (TB) in a Low Incidence Area: A 4-Year Study in Geneva, Switzerland. BMC Infectious Diseases, 9, 217-229. https://doi.org/10.1186/1471-2334-9-217
[34]
Sabawoon, L.W. and Sato, H. (2012) Sex Difference in Tuberculosis in Afghanistan: A National Cohort Study. Mycobacterial Diseases, 2012, 1-5. https://doi.org/10.4172/2161-1068.1000115
[35]
Codlin, A.J., Khowaja, S., Chen, Z., Rahbar, M.H., Qadeer, E., et al. (2011) Short Report: Gender Differences in Tuberculosis Notification in Pakistan. American Journal of Tropical Medicine and Hygiene, 85, 514-517. https://doi.org/10.4269/ajtmh.2011.10-0701
[36]
Muia, P.K., Ngugi, M.P. and Mburu, D.N. (2017) Performance of GeneXpert Assay in Detecting Pulmonary Tuberculosis and Rifampicin Resistance in Patients Attending Kitui County Hospital, Kenya. Journal of Tropical Diseases, 5, Article ID: 1000246. https://doi.org/10.4172/2329-891X.1000246
[37]
Narasimhan, P., Wood, J., Macintyre, C.R. and Mathai, D. (2013) Risk Factors for Tuberculosis. Pulmonary Medicine, 2013, Article ID: 828939. https://doi.org/10.1155/2013/828939
[38]
Morsy, A.M., Zaher, H.H., Hassan, M.H. and Shouman, A. (2003) Predictors of Treatment Failure among Tuberculosis. Patients under DOTS Strategy in Egypt. Eastern Mediterranean Health Journal, 9, 689-701. https://doi.org/10.26719/2003.9.4.618
[39]
De Albuquerque, M.F., Ximenes, R.A., Lucena, S., et al. (2007) Factors Associated with Treatment Failure, Drop Out, and Death in a Cohort of Tuberculosis Patients in Recife, Pernambuco State, Brazil. Cadernos de Saúde Pública, 23, 1573-1582.
[40]
Shargie, E. and Lindtjorn, B. (2007) Determinants of Treatment Adherence among Smear-Positive Pulmonary Tuberculosis Patients in Southern Ethiopia. PLOS Medicine, 4, e37. https://doi.org/10.1371/journal.pmed.0040037
[41]
Rossana, A., et al. (1996) Clinical Predictors of Response to Tuberculosis Chemotherapy. Philippine Journal of Microbiology and Infectious Diseases, 25, 1820.
[42]
Keane, V.P., de Klerk, N., Krieng, T., Hammond, G. and Musk, W.A. (1997) Risk Factors for the Development of Non-Response to First Line Treatment for Tuberculosis in Southern Vietnam. International Journal of Epidemiology, 26, 1115-1120. https://doi.org/10.1093/ije/26.5.1115
[43]
Guerra-Assunção, J.A., Houben, R.M., Crampin, A.C., Mzembe, T., Mallard, K., Coll, F., et al. (2015) Recurrence Due to Relapse or Reinfection with Mycobacterium tuberculosis: A Whole-Genome Sequencing Approach in a Large, Population-Based Cohort with a High HIV Infection Prevalence and Active Follow-Up. The Journal of Infectious Diseases, 211, 1154-1163. https://doi.org/10.1093/infdis/jiu574
[44]
Cox, H., Kebede, Y., Allamuratova, S., Ismailov, G., Davletmuratova, Z., Byrnes, G., et al. (2006) Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance. PLOS Medicine, 3, e384. https://doi.org/10.1371/journal.pmed.0030384
[45]
Shen, X., Yang, C., Wu, J., Lin, S., Gao, X., Wu, Z., et al. (2017) Recurrent Tuberculosis in an Urban Area in China: Relapse or Exogenous Reinfection? Tuberculosis, 103, 97-104. https://doi.org/10.1016/j.tube.2017.01.007
[46]
Ali, M.H., Alrasheedy, A.A., Kibuule, D., Godman, B., Hassali, M.A. and Ali, H.M.H. (2019) Assessment of Multidrug-Resistant Tuberculosis (MDR-TB) Treatment Outcomes in Sudan, Findings and Implications. Expert Review of Anti-Infective Therapy, 17, 927-937. https://doi.org/10.1080/14787210.2019.1689818
[47]
Hirani, N., Joshi, A., Anand, S., Chowdhary, A., Ganesan, K., Agarwal, M. and Phadke, N. (2020) Detection of a Novel Mutation in the rpoB Gene in a Multidrug Resistant Mycobacterium tuberculosis Isolate Using Whole Genome Next Generation Sequencing. Journal of Global Antimicrobial Resistance, 22, 270-274. https://doi.org/10.1016/j.jgar.2020.03.004
